ORIGINAL ARTICLESAripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary studyPessina, Enrico; Albert, Umberto; Bogetto, Filippo; Maina, Giuseppe Author Information Department of Neuroscience, Mood and Anxiety Disorders Unit, University of Turin, Italy Correspondence to Professor Giuseppe Maina, Department of Neurosciences, Mood and Anxiety Disorders Unit, University of Turin, Via Cherasco 11 – 10126 Torino, Italy Tel: +39 011 6335425; fax: +39 011 673473; e-mail: [email protected] Received 20 March 2009 Accepted 26 May 2009 International Clinical Psychopharmacology: September 2009 - Volume 24 - Issue 5 - p 265-269 doi: 10.1097/YIC.0b013e32832e9b91 Buy Metrics Abstract One of the most studied and well-documented strategies for treatment-resistant obsessive–compulsive disorder (OCD) is the addition of antipsychotic drugs to the ongoing serotonin reuptake inhibitor (SRI) treatment. To date, there has been a paucity of data regarding the use of aripiprazole in OCD patients who failed to respond to SRIs. The aim of the present pilot study was to investigate the efficacy of flexible doses of aripiprazole as augmenting agent in the treatment of resistant OCD patients. Patients meeting the inclusion criteria of treatment-resistant OCD entered a 12-week, open-label, flexible-dose trial of aripiprazole addition to SRIs. Aripiprazole was started at 5 mg/day and increased up to a maximum of 20 mg/day. Twelve patients fulfilled entry criteria; nine patients took at least one dose of study medication and eight of them completed the study. The mean daily dosage of aripiprazole in completers was 11.2±5.2 mg/day. Patients showed a significant improvement over the 12-week study period (paired t-test for mean Yale-Brown Obsessive Compulsive Scale total score at week 12 as compared with baseline – all patients: t = 4.860, d.f. = 8, P = 0.001). The most common adverse event reported was inner unrest reported by four (44.4%) patients. Our study supports the notion that adding aripiprazole to SRIs could be a valid strategy for treatment-resistant OCD patients, and points towards the need of randomized, double-blind studies. © 2009 Lippincott Williams & Wilkins, Inc.